contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment CompanyTagList on Company {
  pageUrl
  name
  viewerIsFollowing
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    ...CompanyTagList
    id
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  availableLanguages
  pageUrl
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      defaultInstrument {
        isin
        id
      }
      id
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    id
    name
    viewerIsFollowing
    defaultInstrument {
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


devyser-wins-tender-in-italy-for-its-cystic-fibrosis-ngs-test-worth-up-to-59-million-sek

__typename

title

isPremium

lang

htmlBody

companies

createdAt

publishers

authors

reactionGroups

availableLanguages

pageUrl

imgUrl

description

Devyser Diagnostics develops, manufactures, and sells genetic tests to laboratories globally. The products are used for DNA tests in oncology, transplantation, and hereditary diseases to enable tailored cancer treatment, diagnosis of a large number of genetic diseases, and follow-up of transplant patients. The company is headquartered in Hägersten.

Devyser Diagnostics

Devyser has secured a tender for its cystic fibrosis NGS test, Devyser CFTR. The tender with Policlinico Milano is valid for three years with the possibility of a one-year extension. The estimated...

<div class="mfn-preamble"><p><strong>Devyser has secured a tender for its cystic fibrosis NGS test, Devyser CFTR. The tender with Policlinico Milano is valid for three years with the possibility of a one-year extension. The estimated order value is up to 5.9 million SEK.</strong></p></div><div class="mfn-body"><p>"The tender strengthens our already strong position in the Italian market”, says CEO Fredrik Alpsten.&nbsp;"National and regional screening programs represent important opportunities for us and securing this tender is another confirmation of the competitiveness of our high quality and simple CFTR NGS solutions."&nbsp;</p><p>Cystic fibrosis is a progressive, genetic disease that affects the lungs, pancreas, and other organs.</p><p>Devyser CFTR is a CE-IVD labelled NGS test used in the confirmation of cystic fibrosis and for screening of genetic variants in newborns and adults.&nbsp;Devyser CFTR NGS captures all published cystic fibrosis gene mutations in a single assay that is purpose-designed for fast and efficient lab processing.&nbsp;</p></div><div class="mfn-footer mfn-contacts mfn-6ebf9f6a6a18"><p><strong class="mfn-heading-1">For more information, please contact:</strong><br>Fredrik Alpsten, CEO&nbsp;<br>E-mail: <a rel="noopener" href="mailto:fredrik.alpsten@devyser.com">fredrik.alpsten@devyser.com</a><br>Telephone: +46 70 667 31 06<br>&nbsp;<br>Theis Kipling, CCO<br>E-mail: <a rel="noopener" href="mailto:Theis.kipling@devyser.com">theis.kipling@devyser.com</a>&nbsp;<br>Telephone: +46 73 598 07 76</p></div><div class="mfn-footer mfn-about mfn-89538f97f28b"><p><strong class="mfn-heading-1">About Devyser</strong><br>Devyser develops, manufactures and sells diagnostic solutions and analysis services to clinical laboratories in more than 65 countries. Our products are used for advanced genetic testing in the hereditary disease, oncology and transplant fields, to enable targeted cancer treatment, the diagnosis of a large number of genetic diseases, and transplant patient follow-up. Devyser's products, and unique, patented solution requiring only one test tube, simplify genetic testing processes, improve sample throughput, minimize hands-on time and deliver rapid results. Our goal is for every patient to receive a correct diagnosis in the shortest possible time. Sustainability is a central part of our business and an important prerequisite for long term value creation.</p><p>Devyser was founded in 2004 and is based in Stockholm, Sweden with eight in-house sales offices in Europe and the US. The company also runs Devyser Genomic Laboratories, a CLIA certified laboratory in Atlanta, US. In 2022, Devyser's quality management system was certified according to the IVDR and a number of the company's products have since been certified according to the IVDR.</p><p>Devyser's shares are listed on the Nasdaq First North Premier Growth Market Stockholm (ticker: DVYSR). The company's Certified Adviser is Redeye AB.&nbsp;</p><p>For more information, visit&nbsp;<a rel="noopener" href="http://www.devyser.com/">www.devyser.com</a>.&nbsp;</p></div><div class="mfn-footer mfn-attachment mfn-attachment-general"><p><strong class="mfn-heading-1">Attachments</strong><br><a rel="noopener" href="https://storage.mfn.se/15d3edf5-d900-4920-8eaa-150f1f2dd7fd/devyser-wins-tender-in-italy-for-its-cystic-fibrosis-ngs-test-worth-up-to-5-9-million-sek.pdf" class="mfn-generated mfn-primary">Devyser wins tender in Italy for its cystic fibrosis NGS test worth up to 5.9 million SEK</a></p></div>

Devyser wins tender in Italy for its cystic fibrosis NGS test worth up to 5.9 million SEK

Stay up to date with our newsletter